Document:

exv4w4

Exhibit 4.4

ALIMERA SCIENCES, INC.

SECOND AMENDED AND RESTATED STOCK SALE AGREEMENT

     THIS SECOND AMENDED AND RESTATED STOCK SALE AGREEMENT (the “Agreement”) is made this
17th day of March, 2008, by and among Alimera Sciences, Inc., a Delaware corporation
(the “Company”), the holders of the Company’s Common Stock, par value $0.01 per share (the
“Common Stock”), listed on the Schedule of Common Holders attached as Exhibit A hereto (the
“Common Holders”), the holders of the Company’s Series A Preferred Stock, par value $0.01
per share (the “Series A Stock”), listed on Exhibit B attached hereto (the “Series A
Investors”), the holders of the company’s Series B Preferred Stock, par value $0.01 share (the
“Series B Stock”), listed on Exhibit C hereto (the “Series B Investors”) and the
holders of the Company’s Series C Preferred Stock, par value $0.01 per share (the “Series C
Stock”, and together with the Series A Stock and Series B Stock, the “Preferred
Stock”), listed on Exhibit D attached hereto (the “Series C Investors” and, together
with the Series A Investors and the Series B Investors, the “Investors”). The Common
Holders, the Series A Investors, the Series B Investors, and the Series C Investors, collectively
shall be referred to herein as the “Stockholders.”

RECITALS

     WHEREAS, each Common Holder is the holder of outstanding shares of Common Stock;

     WHEREAS, the Company proposes to obtain equity financing from the Series C Investors pursuant
to that certain Series C Preferred Stock Purchase Agreement, dated as of the date hereof (the
“Series C Purchase Agreement”), by and among the Company and the Series C Investors, which
financing the Company, the Common Holders, the Series A Investors and the Series B Investors
believe to be in the best interests of the Company and its stockholders;

     WHEREAS, the Investors are parties to an Amended and Restated Stock Sale Agreement dated
November 22, 2005 by and among the Company, the Series A Investors, the Series B Investors and the
Common Holders (the “Prior Agreement”);

     WHEREAS, the parties to such Prior Agreement desire to amend and restate the Prior Agreement
and to accept the rights and covenants hereof in lieu of their rights and covenants under the Prior
Agreement; and

     WHEREAS, the Series C Investors have requested, as a condition to entering into the Series C
Purchase Agreement, that the Common Holders, the Series A Investors and the Series B Investors
enter into this Agreement, and the Common Holders, the Series A Investors and the Series B
Investors, as an inducement to the Series C Investors to enter into the Series C Purchase
Agreement, are willing to enter into this Agreement.

 

 

AGREEMENT

     NOW, THEREFORE, in consideration of the premises, and the mutual covenants and terms hereof,
the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows.

     1. Prohibited Transfers. Except for a Permitted Transfer (as defined herein), the
Common Holders shall not sell, assign, transfer, pledge, hypothecate, mortgage or dispose of, by
gift or otherwise, or in any way encumber, whether voluntarily or by operation of law (a
“Transfer”), all or any part of the Shares (as hereinafter defined) owned by them during
the term of this Agreement other than in compliance with the terms of this Agreement. For purposes
of this Agreement, the term “Shares” shall mean and include all shares of capital stock of
the Company owned or held at any time by a Common Holder or by any transferee thereof. Shares
owned or held by a Common Holder shall include shares of capital stock which the Common Holder has
the right to acquire upon the conversion or exercise of all securities convertible into or
exercisable for Common Stock of the Company, and any reference to a Transfer of Shares shall
include a Transfer of such convertible securities.

     2. Rights of First Refusal and Co-Sale.

          2.1 Right of First Refusal.

               (a) If at any time any Common Holder (the “Seller”) desires (or is required) to
Transfer any Shares to a third party other than the Company (the “Buyer”), such Seller
shall provide notice of such proposed sale to the Company and the Investors in accordance with
Section 2.3 hereof, and the Company shall have a period of 15 days after its receipt of such notice
(such date of receipt, the “Notice Date”) to elect to purchase all of the Shares proposed
to be sold or transferred by the Seller (the “Offered Shares”) at the same price per share
and on the same terms and conditions as involved in such sale or disposition. The Company shall
promptly deliver a copy of each such notice to the members of its Board of Directors.

               (b) If the Company does not elect to purchase all of the Offered Shares pursuant to Section
2.1(a), then for a period of 30 days from the Notice Date, each Investor (or any transferee of the
Investor) shall have the right to require, as a condition to such sale or transfer, that the Seller
sell to such Investor (or such transferee) at the same price per share and on the same terms and
conditions as involved in such sale or disposition that percentage (subject to overallotment
rights) of the Offered Shares expressed by a fraction, the numerator of which is the number of
shares of Common Stock (less any shares of Ineligible Stock (as defined below)) and Preferred Stock
(on an as-converted to Common Stock basis) then held by the Investor (or such transferee), and the
denominator of which is the aggregate number of all shares of Common Stock (less all shares of
Ineligible Stock) and Preferred Stock then held by all the Investors and transferees of the
Investors, if any, on an as-converted to Common Stock basis. Notwithstanding the foregoing, any
such Investor may, at the time it accepts the offer, subscribe to purchase any or all securities
offered (“Oversubscription Securities”) which may be available as a result of the
rejection, or partial rejection, of the offer by other Investors. All Oversubscription Securities
shall be offered, on a pro rata basis, to those Investors electing to purchase Oversubscription
Securities. The sale of Oversubscription Securities shall continue pursuant to the process set

2

 

forth in the immediately preceding sentence until all of the Offered Shares have been
purchased by the Investors or until no Investor desires to purchase any remaining Offered Shares.

               (c) Notwithstanding the foregoing, in the event that the Company and the Investors do not
purchase all of the Offered Shares, then the Seller may sell all of the Offered Shares to the
Buyer, except as provided in Section 2.2.

          2.2 Right of Co-Sale. If the Seller desires (or is required) to Transfer any Shares
to a Buyer, each Investor (or any transferee of the Investor) shall have the right, in lieu of
exercise of its right of first refusal as provided in Section 2.1(b) above, to require, as a
condition to such Transfer, that the Buyer purchase from the Investor (or such transferee), that
percentage of the Offered Shares not otherwise purchased by the Company or the Investors pursuant
to Section 2.1 above that is expressed by a fraction, the numerator of which is the number of
shares of Preferred Stock (on an as-converted into Common Stock basis) and Common Stock (less any
shares of Ineligible Stock) then held by the Investor (or such transferee), and the denominator of
which is the number of shares of Preferred Stock (on an as-converted into Common Stock basis) and
Common Stock (less all shares of Ineligible Stock) held by all the Investors and the Seller.

          2.3 Notice. In the event the Seller proposes to undertake a Transfer of Shares, it
shall give the Company, Investors and transferees of the Investors, if any, written notice of its
intention, describing the price and general terms upon which the Seller proposes to transfer
Shares. The Company shall have 15 days, and the Investors and transferees of the Investors, if
any, shall have 30 days from the Notice Date to either (a) exercise the right of first refusal
under Section 2.1 for the price and upon the general terms specified in the notice by giving
written notice to the Seller and stating therein the quantity of Shares to be purchased, or (b) if
applicable, exercise the right of co-sale under Section 2.2 hereof by giving written notice to the
Seller and stating therein the quantity of Shares to be included in the Transfer. The closing of
the Transfer of Shares covered by any such exercise of rights by the Company or Investors pursuant
to Section 2.1 or 2.2 shall occur on the date, if any, set forth in the Seller’s notice pursuant to
this Section 2.3 or on such other date as the parties may agree, provided that if no date
is so specified, the closing shall occur on the date 45 days after the date of the Seller’s notice
pursuant to this Section 2.3, or on such other date as the parties may agree. At the closing, the
selling parties shall deliver certificates representing the securities to be sold, duly endorsed
for Transfer and accompanied by all requisite transfer taxes, if any, and such securities to be
transferred shall be free and clear of any liens, claims or encumbrances (other than restrictions
imposed pursuant to this Agreement and applicable federal and state securities laws), and the
purchasing parties shall deliver payment of the purchase price therefor on the terms described in
the Seller’s written notice pursuant to this Section 2.3.

          2.4 Transfer of Rights. The rights contained in this Section 2 may be assigned or
otherwise conveyed to transferees or assignees of the Investors’ shares of Preferred Stock and
Common Stock issued upon conversion of such Preferred Stock, which transferees or assignees will be
considered “Investors” for purposes hereof.

          2.5 Transfers Constituting Liquidating Event. In the event of any Transfer or
proposed Transfer that, together with all other transfers of shares, or rights to acquire shares,
that are part of the same transaction or series of related transactions, constitutes or would
constitute a

3

 

Liquidating Event for purposes of the Company’s Restated Certificate of Incorporation (the
“Certificate of Incorporation”), then such Transfer may not take place unless and until,
prior to the consummation of such Transfer the Investors shall have been paid in full the amounts
to which they are entitled upon such Liquidating Event under the Certificate of Incorporation.

     3. Permitted Transfers. The rights and transfer restrictions set forth in Section 2
hereof shall not apply to: (a) any Transfer of Shares by gift or bequest or through inheritance
to, or for the benefit of, any spouse, ancestor, sibling or descendant of such individual Common
Holder or any other person approved by a majority of the Board of Directors (including, for this
purpose, a majority of the directors elected by the holders of Preferred Stock pursuant to Article
V, Subsection D.3 of the Company’s Certificate of Incorporation); (b) any Transfer of Shares by an
individual Common Holder to a trust for the benefit of any spouse, ancestor, sibling or descendant
of such Common Holder; (c) a Transfer of Shares by a Common Holder to the Company; and (d) any
Transfer of Shares by a Common Holder that is an entity to such entity’s stockholders, members,
partners or other equity holders (in each case set forth in (a) through (d) above, a “Permitted
Transfer”). Any such Permitted Transfer shall be subject to the terms and provisions of this
Agreement, and the transferee receiving Shares (other than where the Company is the transferee)
shall be bound by the terms and conditions of this Agreement to the same extent as the person
making such Transfer. Each transferee in a Permitted Transfer (other than where the Company is the
transferee) after the date of this Agreement shall execute and deliver to the Company a counterpart
of this Agreement as a condition to the effectiveness of such Permitted Transfer.

     4. Termination. The rights set forth in this Agreement shall terminate upon the
effective date of the closing of an underwritten public offering pursuant to an effective
registration statement under the 1933 Act, covering the offer and sale of Common Stock of the
Company to the public where the Company receives proceeds of $50,000,000 or more (net of
underwriters discounts and commissions), and the price per share to the public is not less than
$5.93, subject to adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization.

     5. Specific Performance. The rights of the parties under this Agreement are unique
and, accordingly, the parties shall, in addition to such other remedies as may be available to any
of them at law or in equity, have the right to enforce their rights hereunder by actions for
specific performance to the extent permitted by law.

     6. Legend. Each certificate held by or issued to the Common Holders, whether now
outstanding or subsequently issued, shall be surrendered to the Company for endorsement or be
endorsed by the Company prior to its issuance with substantially the following legend.

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A STOCK SALE AGREEMENT
AMONG THE HOLDER OF THESE SECURITIES AND CERTAIN OTHER HOLDERS OF THE ISSUER’S
SECURITIES. BY ACCEPTING ANY INTEREST IN SUCH SECURITIES, THE PERSON ACCEPTING SUCH
INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL OF THE PROVISIONS
OF SUCH AGREEMENT. COPIES OF SUCH AGREEMENT MAY BE

4

 

OBTAINED UPON WRITTEN REQUEST BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE
SECRETARY OF THE CORPORATION AT THE PRINCIPAL EXECUTIVE OFFICES OF THE CORPORATION.

     Nothing in this Agreement should be construed as a modification or amendment of any
restrictions on transfer under applicable federal or state securities laws.

     7. Additional Common Holders. The Company shall cause each person or entity hereafter
becoming a holder of shares of the Company’s Common Stock to become a party to this Agreement as a
“Common Holder,” subject to all applicable terms and provisions hereof, by having such
holder execute a signature page hereto and amending Exhibit A pursuant to Section 9.3 below.

     8. Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby
amended in its entirety and restated herein. Such amendment and restatement is effective upon the
execution of this Agreement by the Company, the holders of at least two-thirds (2/3) of the
outstanding Common Stock as of the date of this Agreement held by the Common Holders providing
services to the Company as an officer, employee or consultant, and the holders of at least a
majority of the outstanding Preferred Stock as of the date of this Agreement. Upon such execution,
all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived,
released and superseded in their entirety and shall have no further force or effect.

     9. General Provisions.

          9.1 Governing Law. This Agreement shall be governed by the laws of the State of
Delaware without regard to choice of law provisions.

          9.2 Entire Agreement. This Agreement constitutes the entire agreement among the
parties with respect to the subject matter hereof and supersedes all prior agreements and
understandings between them or any of them as to such subject matter. This Agreement shall be
binding upon and shall inure to the benefit of the parties hereto and their heirs, executors, legal
representative, successors and permitted transferees, except as may be expressly provided otherwise
herein.

          9.3 Amendments and Waivers. Except as otherwise expressly provided herein, this
Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance, either retroactively or prospectively and either for a
specified period of time or indefinitely) only upon the written consent of: (a) the Company, (b)
the holders of at least a majority of the then outstanding Common Stock held by the Common Holders
then providing services to the Company as an officer, employee or consultant, and (c) the holders
of at least a majority of the then outstanding Preferred Stock held by the Investors.
Notwithstanding anything to the contrary in this Section 9.3, the Company shall be entitled to in
accordance with Section 7, include additional holders of its Common Stock as parties to this
Agreement, and to treat such holders as “Common Holders” hereunder by having each such
holder execute a signature page hereto, amending Exhibit A attached hereto and providing such
amended Exhibit A to the other parties to this Agreement.

5

 

          9.4 Severability. In the case any one or more of the provisions contained in this
Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other provision of this Agreement
and such invalid, illegal and unenforceable provision shall be reformed and construed so that it
will be valid, legal, and enforceable to the maximum extent permitted by law.

          9.5 Successors and Assigns. The provisions hereof shall inure to the benefit of, and
be binding upon, the parties hereto and their respective successors, assigns, heirs, executors and
administrators and other legal representatives.

          9.6 Ownership. Each Common Holder represents and warrants that he, she or it is the
sole legal and beneficial owner of those Shares he or she currently holds subject to this Agreement
and that no other person has any interest (other than a community property interest) in such
shares.

          9.7 Notice. Any notice required or permitted under this Agreement shall be given in
writing and shall be deemed effectively given and received: (a) upon personal delivery to the party
to be notified; (b) upon delivery by confirmed facsimile or electronic transmission if received by
the recipient before 5:00 p.m. local time on a business day, and if not, then the next business
day; (c) if to a U.S. resident, five (5) days after deposit with the United States Post Office, by
registered or certified mail, postage prepaid; or (d) if to a U.S. resident, one (1) business day
after deposit with a nationally recognized overnight courier service (or if to a non-U.S. resident,
two (2) business days after deposit with an internationally recognized overnight courier service,
specifying international priority delivery), and addressed to the parties at the addresses of the
parties set forth at the end of this Agreement or such other address as a party may request by
notifying the other in writing.

          9.8 Attorneys’ Fees. In the event that any suit or action is instituted under or in
relation to this Agreement, including without limitation to enforce any provision in this
Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party
all fees, costs and expenses of enforcing any right of such prevailing party under or with respect
to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and
accountants, which shall include, without limitation, all fees, costs and expenses of appeals.

          9.9 Delays or Omissions. Any party’s failure to enforce any provision or provisions
of this Agreement shall not in any way be construed as a waiver of any such provision or
provisions, nor prevent that party thereafter from enforcing each and every other provision of this
Agreement. The rights granted to the parties herein are cumulative and not alternative.

          9.10 Intent. The Stockholders agree to execute upon request any further documents or
instruments necessary or desirable to carry out the purposes or intent of this Agreement.

          9.11 Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be enforceable against the parties actually executing such counterparts, and all of
which together shall constitute one instrument.

6

 

[Remainder of page intentionally left blank]

7

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	COMPANY:
	 
	 	 	 	 
	 	 	ALIMERA SCIENCES, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	INTERSOUTH PARTNERS V, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Intersouth Associates V, L.P.,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	INTERSOUTH AFFILIATES V, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Intersouth Associates V, LLC,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	INTERSOUTH PARTNERS VI, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Intersouth Associates VI, LLC,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	INTERSOUTH PARTNERS VII, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Intersouth Associates VII, L.P.,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	VENROCK PARTNERS, L.P.
	 	 	by its General Partner,
Venrock Partners Management, LLC
	 
	 	 	 	 
	 	 	VENROCK ASSOCIATES IV, L.P.
	 	 	by its General Partner, Venrock Management IV, LLC
	 
	 	 	 	 
	 	 	VENROCK ENTREPRENEURS FUND IV, L.P.
	 	 	by its General Partner, VEF Management IV, LLC
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:
	 	 Member

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	BAVP, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	BA Venture Partners VI, LLC,
	 

	 	 	 	its general partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	 	 	Managing Director

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS IV, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Polaris Venture Management Co. IV, L.L.C.,
	 

	 	 	 	its General Partner
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	POLARIS VENTURE
PARTNERS ENTREPRENEURS’ FUND IV, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	Polaris Venture Management Co. IV, L.L.C.,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	DOMAIN PARTNERS VI, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	One Palmer Square Associates VI, L.L.C.,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	DP VI ASSOCIATES, L.P.
	 
	 	 	 	 
	 

	 	By:
	 	One Palmer Square Associates VI, L.L.C.,
	 

	 	 	 	its General Partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTORS:
	 
	 	 	 	 
	 	 	G&H PARTNERS
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	INVESTOR/COMMON HOLDER:
	 
	 	 	 	 
	 	 	 
	 	 	Dr. Calvin Roberts

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

     IN WITNESS WHEREOF, this Second Amended and Restated Stock Sale Agreement has been duly
executed and delivered by the parties as of the date first above written.

	 	 	 	 	 
	 	 	COMMON STOCKHOLDERS:
	 
	 	 	 	 
	 	 	 
	 	 	C. Daniel Myers
	 
	 	 	 	 
	 	 	 
	 	 	David Holland
	 
	 	 	 	 
	 	 	 
	 	 	Alisa Hudzina
	 
	 	 	 	 
	 	 	 
	 	 	Susan Caballa
	 
	 	 	 	 
	 	 	 
	 	 	David Eitel

Signature Page to

Second Amended and Restated Stock Sale Agreement

 

 

EXHIBIT A

SCHEDULE OF COMMON HOLDERS

	 	 	 	 	 
	Name and Address of Common Holder1	 	No. of Shares of Common Stock
	Alisa Hudzina
	 	 	100,000	 
	 
	Amanda Whittington and Scott Whittington, JTWROS
	 	 	2,500	 
	 
	Arthur Murray
	 	 	25,000	 
	 
	Barry Dabbs
	 	 	25,000	 
	 
	BFG Investments, LLC
	 	 	18,448	 
	 
	Brian Burks
	 	 	1,250	 
	 
	Brian Whitright
	 	 	208,083	 
	 
	Bryan & Mary Grissett
	 	 	50,000	 
	 
	Buddy King
	 	 	250,000	 
	 
	Barry Burden and Michelle Howard Burden, JTWROS
	 	 	1,563	 
	 
	C&B Capital, LP

	 	 	 	 
	 
	C. Daniel Myers
	 	 	1,100,000	 
	 
	Calvin Roberts
	 	 	300,000	 
	 
	Charles Bradford Myers
	 	 	10,000	 
	 
	Charles Myers
	 	 	5,000	 
	 
	Chris Freund
	 	 	8,334	 
	 
	Corissa Vossbrink
	 	 	2,500	 
	 
	Daniel White
	 	 	550,000	 

 

			
	1	 	Address as set forth in the Company’s stock records.

E-1 

 

	 	 	 	 	 
	Name and Address of Common Holder1	 	No. of Shares of Common Stock
	David Eitel
	 	 	10,000	 
	 
	David Hollan
	 	 	400,000	 
	 
	David K. and Gail Z. Kinser
	 	 	5,000	 
	 
	David Preston White
	 	 	5,000	 
	 
	Davis Myers
	 	 	20,000	 
	 
	DC&B Partnership
	 	 	9,224	 
	 
	Deanna Magdich
	 	 	20,000	 
	 
	Deborah Chafin and David Chafin, Community Property
	 	 	16,666	 
	 
	Domain Partners VI, LP
	 	 	 	 
	 
	Don Testerman
	 	 	5,000	 
	 
	Evan Myers
	 	 	20,000	 
	 
	Frances Kane
	 	 	28,125	 
	 
	George Ritacco
	 	 	8,333	 
	 
	Grayson Davis Myers
	 	 	5,000	 
	 
	Greta Myers
	 	 	5,000	 
	 
	Holly Reynerson and Jayme K. Reynerson,
as Community Property
	 	 	2,500	 
	 
	J. Randall Carroll
	 	 	100,000	 
	 
	James D. Loftin
	 	 	10,000	 
	 
	James Seifert II
	 	 	12,500	 
	 
	Jean Norris
	 	 	3,563	 
	 
	Jeff Bradsha
	 	 	10,000	 
	 
	Jeff German and Marianne German, JTWROS
	 	 	12,500	 

E-2 

 

	 	 	 	 	 
	Name and Address of Common Holder1	 	No. of Shares of Common Stock
	Jeff Holden and Rhonda E. Holden, Community Property
with the Right of Survivorship
	 	 	3,594	 
	 
	Jeffrey Mason
	 	 	10,000	 
	 
	Jennifer Burnette
	 	 	5,000	 
	 
	Jessica Robinson
	 	 	5,625	 
	 
	Jim Harris
	 	 	8,333	 
	 
	Joan Kaimer (Trust)
	 	 	50,000	 
	 
	Katherine Booms
	 	 	100	 
	 
	Kari Kubala
	 	 	2,500	 
	 
	Karen Hutton Powell and Matthew Blake Powell, JTWROS
	 	 	17,813	 
	 
	Karen Myers
	 	 	15,000	 
	 
	Keith Jeremy Caballa
	 	 	25,000	 
	 
	Keith Seifert Sr.
	 	 	12,500	 
	 
	Kelly Seifert and Kevin Seifert, JTWROS
	 	 	1,250	 
	 
	Kerry Jo Nantz
	 	 	5,000	 
	 
	Kevin Carroll
	 	 	10,000	 
	 
	Linda T. and Jimmy D. Veal
	 	 	21,085	 
	 
	Mark Testerman
	 	 	400,000	 
	 
	Mark Testerman and Sara Sue Testerman,
JTWROS
	 	 	107,495	 
	 
	Nancy Boyd
	 	 	5,000	 
	 
	Patrick Hickock
	 	 	100,000	 
	 
	Paul David Kinser
	 	 	5,000	 

E-3 

 

	 	 	 	 	 
	Name and Address of Common Holder1	 	No. of Shares of Common Stock
	Paul Linck
	 	 	9,224	 
	 
	Plunkett Family LP
	 	 	9,224	 
	 
	Randy Rhino
	 	 	10,000	 
	 
	REDLOH Capital, LLC
	 	 	9,224	 
	 
	Richard Lamar Wakefield
	 	 	25,000	 
	 
	Robert & Nancy Sharp
	 	 	25,000	 
	 
	Robert Thomas Cooksey
	 	 	25,000	 
	 
	Rose Berube
	 	 	2,500	 
	 
	Scott Kilburn
	 	 	25,000	 
	 
	Sharon Louise Hill (fka, Hugh Hill)
	 	 	52,651	 
	 
	SOLFAM Trust
	 	 	363,256	 
	 
	Susan Caballa
	 	 	175,000	 
	 
	Susan Liguori
	 	 	25,000	 
	 
	Susan Thomspon
	 	 	5,000	 
	 
	Thomas Davenport
	 	 	25,000	 
	 
	Thomas L. Shields
	 	 	9,224	 
	 
	Timothy Czerwionka and Rebekah Czerwionka, as
Community Property
	 	 	2,500	 
	 
	Tony Catanzaro
	 	 	25,000	 
	 
	Tracy Aiken
	 	 	50,000	 
	 
	Tracy Puckett and Etienne Puckett, JTWROS
	 	 	46,748	 
	 
	UBS Financial Services
	 	 	25,000	 
	 
	Virginia Morris
	 	 	5,000	 
	 
	White Family Trust
	 	 	30,000	 

E-4 

 

EXHIBIT B

SCHEDULE OF SERIES A INVESTORS

	 	 	 	 	 
	Name and Address	 	Shares of Series A Stock
	Intersouth Partners V, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	2,539,618	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865

	 	 	 	 
	 
	 	 	 	 
	Intersouth Affiliates V, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	116,096	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865

	 	 	 	 

E-5

 

	 	 	 	 	 
	Name and Address	 	Shares of Series A Stock
	Intersouth Partners VI, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	2,655,715	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865

	 	 	 	 
	 
	 	 	 	 
	BAVP, L.P.

950 Tower Lane

Suite 700

Foster City, CA 94044

Attn: Mark Brooks

Facsimile: (650) 378-6040

	 	 	5,311,429	 
	 
	 	 	 	 
	Domain Partners VI, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542

Attn: Brian Halak

Facsimile: (609) 683-4581

	 	 	5,255,110	 
	 
	 	 	 	 
	DP VI Associates, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542

Attn: Brian Halak

Facsimile: (609) 683-4581

	 	 	56,319	 
	 
	 	 	 	 
	Polaris Venture Partners IV, L.P.

1000 Winter Street, Suite 3350

Waltham, MA 02451

Attn: Bryce Youngren

Fax: (781) 290-0880

	 	 	5,219,317	 

E-6

 

	 	 	 	 	 
	Name and Address	 	Shares of Series A Stock
	Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.

1000 Winter Street, Suite 3350

Waltham, MA 02451

Attn: Bryce Youngren

Fax: (781) 290-0880

	 	 	92,112	 
	 
	 	 	 	 
	C&B Capital, L.P.

4200 Northside Parkway, N.W.

Building One, Suite 100

Atlanta, Georgia 30327

Attn: Theodore J. Bender, III

	 	 	632,564	 
	 
	 	 	 	 
	Thomas L. Shields, Jr.

1750 W. Sussex

Atlanta, GA 30306

	 	 	36,899	 
	 
	 	 	 	 
	BFG Investments, LLC

(Robert B. Braden)

931 Ponce de Leon Ave, NE

Atlanta, GA 30306

	 	 	36,899	 
	 
	 	 	 	 
	BFG Investments, LLC

(Peter B. Fellman)

931 Ponce de Leon Ave, NE

Atlanta, GA 30306

	 	 	36,899	 
	 
	 	 	 	 
	REDLOH Capital, LLC

3333 Riverwood Parkway,

Suite 400

Atlanta, GA 30339

Attn: J.C. Pendrey, Jr.

	 	 	36,899	 
	 
	 	 	 	 
	Linda T. and Jimmy D. Veal

290 Osprey Place

Brunswick, GA 31525

	 	 	84,342	 
	 
	 	 	 	 
	Sharon Louise Hill

4027 River Ridge Chase

Marietta, GA 30067

	 	 	50,605	 
	 
	 	 	 	 
	DC&M Partnership

41 Muscogee Ave. N.W.

Atlanta, GA 30305

Attn: David F. Walbert

	 	 	36,899	 

E-7

 

	 	 	 	 	 
	Name and Address	 	Shares of Series A Stock
	SOLFAM Trust

Philip Solomons, Tstee

5 Mad Anthony Lane

Savannah, GA 31411

	 	 	253,025	 
	 
	 	 	 	 
	Plunkett Family, LP

L. Richard Plunkett, Managing Partner

196 Folds Road

Carrollton, GA 30116

	 	 	36,899	 
	 
	 	 	 	 
	Paul Linck

419 Mill Creek Bend

Atlanta, GA 30307

	 	 	36,899	 

E-8

 

EXHIBIT C

SCHEDULE OF SERIES B INVESTORS

	 	 	 	 	 
	Name and Address	 	Shares of Series B Stock
	Venrock Associates IV, L.P.

2494 Sand Hill Road, Suite 200

Menlo Park, CA 94025

Attn: Anders Hove

Facsimile: (650) 561-9180

	 	 	6,209,758	 
	 
	 	 	 	 
	Venrock Entrepreneurs’ Fund IV, L.P.

2494 Sand Hill Road, Suite 200

Menlo Park, CA 94025

Attn: Anders Hove

Facsimile: (650) 561-9180

	 	 	152,574	 
	 
	 	 	 	 
	Venrock Partners, L.P.

2494 Sand Hill Road, Suite 200

Menlo Park, CA 94025

Attn: Anders Hove

Facsimile: (650) 561-9180

	 	 	1266,364	 
	 
	 	 	 	 
	Intersouth Partners V, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	1,823,258	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865
	 	 	 	 

E-9

 

	 	 	 	 	 
	Name and Address	 	Shares of Series B Stock
	Intersouth Affiliates V, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	83,914	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865
	 	 	 	 
	 
	 	 	 	 
	Intersouth Partners VI, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	1,907,176	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865
	 	 	 	 
	 
	 	 	 	 
	BAVP, L.P.

950 Tower Lane

Suite 700

Foster City, CA 94044

Attn: Mark Brooks

Facsimile: (650) 378-6040

	 	 	3,814,348	 
	 
	 	 	 	 
	Domain Partners VI, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542

Attn: Brian Halak

Facsimile: (609) 683-4581

	 	 	3,773,902	 

E-10

 

	 	 	 	 	 
	Name and Address	 	Shares of Series B Stock
	DP VI Associates, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542

Attn: Brian Halak

Facsimile: (609) 683-4581

	 	 	40,446	 
	 
	 	 	 	 
	Polaris Venture Partners IV, L.P.

1000 Winter Street, Suite 3350

Waltham, MA 02451

Attn: Bryce Youngren

Fax: (781) 290-0880

	 	 	3,744,138	 
	 
	 	 	 	 
	Polaris Venture Partners Entrepreneurs’
Fund IV, L.P.

1000 Winter Street, Suite 3350

Waltham, MA 02451

Attn: Bryce Youngren

Fax: (781) 290-0880

	 	 	70,210	 
	 
	 	 	 	 
	C&B Capital, L.P.
4200 
Northside Parkway, N.W.

Building One, Suite 100

Atlanta, Georgia 30327

Attn: Theodore J. Bender, III

	 	 	515,740	 
	 
	 	 	 	 
	Thomas L. Shields, Jr.

1750 W. Sussex

Atlanta, GA 30306

	 	 	38,694	 
	 
	 	 	 	 
	BFG Investments, LLC

(Robert B. Braden)

931 Ponce de Leon Ave, NE

Atlanta, GA 30306

	 	 	38,694	 
	 
	 	 	 	 
	BFG Investments, LLC

(Peter B. Fellman)

931 Ponce de Leon Ave, NE

Atlanta, GA 30306

	 	 	38,694	 
	 
	 	 	 	 
	REDLOH Capital, LLC

3333 Riverwood Parkway,

Suite 400

Atlanta, GA 30339

Attn: J.C. Pendrey, Jr.

	 	 	38,694	 

E-11

 

	 	 	 	 	 
	Name and Address	 	Shares of Series B Stock
	Linda T. and Jimmy D. Veal

290 Osprey Place

Brunswick, GA 31525

	 	 	44,217	 
	 
	 	 	 	 
	Sharon Louise Hill

4027 River Ridge Chase

Marietta, GA 30067

	 	 	13,060	 
	 
	 	 	 	 
	DC&M Partnership

41 Muscogee Ave. N.W.

Atlanta, GA 30305

Attn: David F. Walbert

	 	 	38,694	 
	 
	 	 	 	 
	SOLFAM Trust

Philip Solomons, Tstee

5 Mad Anthony Lane

Savannah, GA 31411

	 	 	265,299	 
	 
	 	 	 	 
	Plunkett Family, LP

L. Richard Plunkett, Managing Partner

196 Folds Road

Carrollton, GA 30116

	 	 	38,694	 
	 
	 	 	 	 
	Paul Linck

419 Mill Creek Bend

Atlanta, GA 30307

	 	 	38,694	 
	 
	 	 	 	 
	Dr. Calvin Roberts

	 	 	223,425	 
	 
	 	 	 	 
	Daniel D. Veal

136 Foxcreek Boulevard

Brunswick, GA 31523

	 	 	22,108	 
	 
	 	 	 	 
	Zachry T. Veal

138 Foxcreek Boulevard

Brunswick, GA 31523

	 	 	22,108	 
	 
	 	 	 	 
	Irene T. Kramer and Jerry D. Kramer JTWROS

3882 The Ascent NE

Atlanta, GA 30319

	 	 	10,000	 
	 
	 	 	 	 
	Janice Dee Weber

849 Chestnut Lake Drive NE

Marietta, GA 30068

	 	 	10,000	 

E-12

 

	 	 	 	 	 
	Name and Address	 	Shares of Series B Stock
	James Loftin

6630 Chambrel Way

Sawanee, GA 30024

	 	 	10,000	 
	 
	 	 	 	 
	Michel Benton

802 Sterling Falls Circle

Canton, GA 30114

	 	 	10,000	 

E-13

 

EXHIBIT C

SCHEDULE OF SERIES C INVESTORS

	 	 	 	 	 
	Name and Address	 	Shares of Series C Stock
	Venrock Associates IV, L.P.

2494 Sand Hill Road, Suite 200

Menlo Park, CA 94025

Attn: Anders Hove

Facsimile: (650) 561-9180

	 	 	2,585,253	 
	 
	 	 	 	 
	Venrock Entrepreneurs’ Fund IV, L.P.

2494 Sand Hill Road, Suite 200

Menlo Park, CA 94025

Attn: Anders Hove

Facsimile: (650) 561-9180

	 	 	63,519	 
	 
	 	 	 	 
	Venrock Partners, L.P.

2494 Sand Hill Road, Suite 200

Menlo Park, CA 94025

Attn: Anders Hove

Facsimile: (650) 561-9180

	 	 	527,214	 
	 
	 	 	 	 
	Intersouth Partners VII, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	1,961,322	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865
	 	 	 	 

E-14

 

	 	 	 	 	 
	Name and Address	 	Shares of Series C Stock
	Intersouth Partners VI, L.P.

3211 Shannon Road, Suite 610

Durham, NC 27707

Attn: Philip Tracy

Facsimile: (919) 493-6649

	 	 	1,961,325	 
	 
	 	 	 	 
	with a copy to:
	 	 	 	 
	 
	 	 	 	 
	Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attn: Anthony L. Williams

Telephone: 919-781-4000

Facsimile: 919-781-4865
	 	 	 	 
	 
	 	 	 	 
	BAVP, L.P.

950 Tower Lane

Suite 700

Foster City, CA 94044

Attn: Mark Brooks

Facsimile: (650) 378-6040

	 	 	3,922,648	 
	 
	 	 	 	 
	Domain Partners VI, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542

Attn: Brian Halak

Facsimile: (609) 683-4581

	 	 	3,881,055	 
	 
	 	 	 	 
	DP VI Associates, L.P.

One Palmer Square, Suite 515

Princeton, NJ 08542

Attn: Brian Halak

Facsimile: (609) 683-4581

	 	 	41,594	 
	 
	 	 	 	 
	Polaris Venture Partners IV, L.P.

1000 Winter Street, Suite 3350

Waltham, MA 02451

Attn: Bryce Youngren

Fax: (781) 290-0880

	 	 	3,850,464	 

E-15

 

	 	 	 	 	 
	Name and Address	 	Shares of Series C Stock
	Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.

1000 Winter Street, Suite 3350

Waltham, MA 02451

Attn: Bryce Youngren

Fax: (781) 290-0880

	 	 	72,185	 
	 
	 	 	 	 
	Dr. Calvin Roberts

	 	 	217,913	 
	 
	 	 	 	 
	Janice Dee Weber

849 Chestnut Lake Drive NE

Marietta, GA 30068

	 	 	3,328	 
	 
	 	 	 	 
	REDLOH Capital, LLC

JC Pendrey, Jr.

3333 Riverwood Parkway, Suite 400

Atlanta, GA 30339

	 	 	30,294	 
	 
	 	 	 	 
	Irene T. Kramer and Jerry D. Kramer JTWROS

3882 The Ascent NE

Atlanta, GA 30319

	 	 	3,328	 
	 
	 	 	 	 
	BFG Investments LLC (Braden)

Robert B. Braden

931 Ponce de Leon Avenue

Atlanta, GA 30306

	 	 	30,294	 
	 
	 	 	 	 
	BFG Investments LLC (Fellman)

Robert B. Braden

931 Ponce de Leon Avenue

Atlanta, GA 30306

	 	 	30,294	 
	 
	 	 	 	 
	Thomas L. Shields, Jr.

1750 W Sussex

Atlanta, GA 30306

	 	 	29,579	 
	 
	 	 	 	 
	C&B Capital II, L.P.

Edward S. Croft, III, its Manager

C&B Capital II GP, LLC, its General Partner

c/o Croft & Bender LLC

Building One, Suite 100

4200 Northside Parkway, NW

Atlanta, GA 30327

	 	 	216,879	 

E-16

 

	 	 	 	 	 
	Name and Address	 	Shares of Series C Stock
	C&B Capital II (PF), L.P.

Edward S. Croft, III, its Manager

C&B Capital II GP, LLC, its General
Partner

c/o Croft & Bender LLC

Building One, Suite 100

4200 Northside Parkway, NW

Atlanta, GA 30327

	 	 	178,006	 
	 
	 	 	 	 
	James Loftin

6630 Chambrel Way

Sawanee, GA 30024

	 	 	6,656	 
	 
	 	 	 	 
	Sharon Louise Hill

4027 River Ridge Chase

Marietta, GA 30067

	 	 	40,563	 
	 
	 	 	 	 
	Michel Benton

802 Sterling Falls Circle

Canton, GA 30114

	 	 	3,328	 
	 
	 	 	 	 
	Linda T. and Jimmy D. Veal

290 Osprey Place

Brunswick, GA 31525

	 	 	32,908	 
	 
	 	 	 	 
	Daniel D. Veal

136 Foxcreek Boulevard

Brunswick, GA 31523

	 	 	7,358	 
	 
	 	 	 	 
	Zachry T. Veal

138 Foxcreek Boulevard

Brunswick, GA 31523

	 	 	7,358	 
	 
	 	 	 	 
	Paul Linck

419 Mill Creek Boulevard

Atlanta, GA 30307

	 	 	29,579	 
	 
	 	 	 	 
	G&H Partners

155 Constitution Drive

Menlo Park, CA 71429

	 	 	10,002	 

E-17exv4w5

Exhibit 4.5

OMNIBUS AMENDMENT

     THIS OMNIBUS AMENDMENT (the “Agreement”) is made and entered into as of August 25, 2009
between Alimera Sciences, Inc., a Delaware corporation (the “Company”) and each person or entity
identified as a “Stockholder” on the signature pages hereto (each a “Stockholder” and collectively,
the “Stockholders”).

RECITALS

     WHEREAS, the Company proposes to issue shares of its Series C-1 Preferred Stock and warrants
to purchase shares of its Series C-1 Preferred Stock (the “Series C-1 Financing”) pursuant to the
terms and conditions of that certain Series C-1 Preferred Stock and Warrant Purchase Agreement of
even date herewith (the “Stock Purchase Agreement”);

     WHEREAS, certain of the Stockholders are parties to each of (i) that certain Second Amended
and Restated Investor Rights Agreement, dated as of March 17, 2008, by and among the Company and
certain holders of the Company’s capital stock (the “Investor Rights Agreement”) and (ii) that
certain Second Amended and Restated Stock Sale Agreement, dated as of March 17, 2008, by and among
the Company and certain holders of the Company’s capital stock (the “Stock Sale Agreement”);

     WHEREAS, pursuant to Section 7.5 of the Investor Rights Agreement, any term of the Investor
Rights Agreement may be amended with the written consent of the Company and the Investors holding
at least two-thirds (2/3) of the shares of Investor Stock (as defined therein), voting together as
a single group, and including, for such purposes, shares of Common Stock into which any shares of
Investor Stock have been converted (collectively, the “IRA Requisite Parties”);

     WHEREAS, pursuant to Section 9.3 of the Stock Sale Agreement, any term of the Stock Sale
Agreement may be amended with the written consent of the Company, the holders of at least a
majority of the then outstanding Common Stock held by the Common Holders then providing services to
the Company as an officer, employee or consultant, and the holders of at least a majority of the
then outstanding Preferred Stock held by the Investors (each as defined therein) (collectively, the
“Stock Sale Agreement Requisite Parties”);

     WHEREAS, Dr. Calvin Roberts is an Eligible Holder (as defined in the Investor Rights
Agreement) with a right to purchase his Pro Rata Share (as defined in the Investor Rights
Agreement) of Series C-1 Units issued by the Company in the Series C-1 Financing;

     WHEREAS, Dr. Roberts desires to assign such right to purchase Series C-1 Units to the Calvin
W. Roberts MD PC Pension Plan (the “Roberts Pension Plan”), such that the Roberts Pension Plan
shall purchase Series C-1 Units issued pursuant to the Stock Purchase Agreement in the Series C-1
Financing; provided, however, that as a condition with such purchase, the Roberts Pensions Plan
shall become a party to each of the Investor Rights Agreement and the Stock Sale Agreement; and

     WHEREAS, in connection with the Series C-1 Financing, the Company and the undersigned
Stockholders, constituting both the IRA Requisite Parties and the Stock Sale

 

 

Agreement Requisite Parties, desire to amend the Investor Rights Agreement and the Stock Sale
Agreement as set forth herein and to consent to the admission of the Roberts Pension Plan as a
party to each such agreement.

AGREEMENT

     NOW, THEREFORE, in consideration of the promises and conditions contained herein, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereby agree as follows:

	 	1.	 	Amendment of Investor Rights Agreement. Upon execution of this
Agreement by the IRA Requisite Parties, the Investor Rights Agreement shall be amended
as follows:

	 	a.	 	A new exhibit, in the form attached hereto as
Attachment 1, shall be added to the Investor Rights Agreement as Exhibit F
thereto.

	 	b.	 	The parties to the Investor Rights Agreement shall be
deemed to include the investors listed on Exhibit F thereto (as attached by
operation hereof), which such parties shall be referred to for purposes of
such agreement as the “Series C-1 Investors”. The definition of
“Investors” therein shall be amended to include such Series C-1 Investors.

	 	c.	 	The definition of “Investor Stock” shall be amended to
include shares of the Company’s Series C-1 Preferred Stock, par value $0.01
per share, including shares issued or issuable upon exercise of warrants
exercisable therefor.

	 	2.	 	Amendment of Stock Sale Agreement. Upon execution of this Agreement by
the Stock Sale Requisite Parties, the Stock Sale Agreement shall be amended as
follows: 

	 	a.	 	A new exhibit, in the form attached hereto as
Attachment 1, shall be added to the Stock Sale Agreement as Exhibit E
thereto.

	 	b.	 	The parties to the Stock Sale Agreement shall be deemed
to include the investors listed on Exhibit E thereto (as attached by
operation hereof), which such parties shall be referred to for purposes of
such agreement as the “Series C-1 Investors”. The definition of each of
“Investors” and “Stockholders” shall be amended to include such Series C-1
Investors.

	 	c.	 	The definition of “Preferred Stock” shall be amended to
include shares of the Company’s Series C-1 Preferred Stock, par value $0.01
per share, including shares issued or issuable upon exercise of warrants
exercisable therefor.

 

 

	 	3.	 	Roberts Pension Plan.

	 	a.	 	By its signature below, the Roberts Pension Plan hereby
agrees, effective as of the date hereof, to be bound by and to become party
to the Investor Rights Agreement and the Stock Sale Agreement, each as may
be amended from time to time (including, without limitation, by this
Agreement), in each case as a “Series C-1 Investor”. The Roberts Pension
Plan further acknowledges that its signature page attached to this
agreement shall be deemed a counterpart signature page to each of the
Investor Rights Agreement and the Stock Sale Agreement and, as such, may be
attached to each such agreement.

	 	b.	 	Each Stockholder hereby consents to the assignment by
Dr. Roberts of his right under the Investor Rights Agreement to purchase
Series C-1 Units to the Roberts Pension Plan; provided, however, that such
consent is expressly conditioned on the execution and delivery by the
Roberts Pension Plan of this Agreement.

	 	c.	 	Upon execution of this Agreement by each of (i) the IRA
Requisite Parties, (ii) the Stock Sale Agreement Requisite Parties and
(iii) the Roberts Pension Plan, each of Investor Rights Agreement and the
Stock Sale Agreement shall be amended to include the Roberts Pension Plan
as a party thereto, in each case as a “Series C-1 Investor”.

	 	4.	 	General.

	 	a.	 	Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding
upon the respective successors and assigns of the parties hereto.

	 	b.	 	Except as expressly provided herein, all provisions of
each of the Investor Rights Agreement and the Stock Sale Agreement shall
remain in full force and effect.

	 	c.	 	This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to
Delaware conflict of law principles.

	 	d.	 	This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	COMPANY:	 	 
	 
	 	 	 	 	 	 
	 	 	ALIMERA SCIENCES, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDER:	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Dr. Calvin Roberts	 	 
	 
	 	 	 	 	 	 
	 	 	ROBERTS PENSION PLAN:	 	 
	 
	 	 	 	 	 	 
	 	 	CALVIN W. ROBERTS MD PC PENSION PLAN	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	VENROCK PARTNERS, L.P.	 	 
	 	 	by its General Partner, Venrock Partners	 	 
	 	 	Management, LLC	 	 
	 
	 	 	 	 	 	 
	 	 	VENROCK ASSOCIATES IV, L.P.

by its General Partner, Venrock Management IV, LLC	 	 
	 
	 	 	 	 	 	 
	 	 	VENROCK ENTREPRENEURS FUND IV, L.P.	 	 
	 	 	by its General Partner, VEF Management IV, LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

Member
	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	INTERSOUTH PARTNERS VII, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Intersouth Associates VII, L.P.,

its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Philip Tracy	 	 
	 	 	Title: Member, acting pursuant to Power of Attorney	 	 
	 
	 	 	 	 	 	 
	 	 	INTERSOUTH PARTNERS V, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Intersouth Associates V, L.P.,

its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Name: Philip Tracy	 	 
	 	 	Title: Member, acting pursuant to Power of Attorney	 	 
	 
	 	 	 	 	 	 
	 	 	INTERSOUTH AFFILIATES V, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Intersouth Associates V, LLC,	 	 
	 

	 	 	 	its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Philip Tracy	 	 
	 	 	Title: Member, acting pursuant to Power of Attorney	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	INTERSOUTH PARTNERS VI, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Intersouth Associates VI, LLC,	 	 
	 

	 	 	 	its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Philip Tracy	 	 
	 	 	Title: Member, acting pursuant to Power of Attorney	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	BAVP, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Scale Venture Management I, LLC	 	 
	 

	 	Its:
	 	general partner	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Name: Mark Brooks	 	 
	 	 	Title: Managing Director	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Polaris Venture Management Co. IV, L.L.C.,	 	 
	 

	 	 	 	its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND IV, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Polaris Venture Management Co. IV, L.L.C.,	 	 
	 

	 	 	 	its General Partner	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	DOMAIN PARTNERS VI, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	One Palmer Square Associates VI, L.L.C.,	 	 
	 

	 	 	 	its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	DP VI ASSOCIATES, L.P.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	One Palmer Square Associates VI, L.L.C.,	 	 
	 

	 	 	 	its General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 	 	 
	 	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 	 	 
	 	 	G&H PARTNERS	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	Name:
	 	 

	 	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 	 	 

	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

          IN WITNESS WHEREOF, this Omnibus Amendment has been duly executed and delivered by the parties
as of the date first above written.

	 	 	 	 	 
	 

	 	STOCKHOLDERS:	 	 
	 
	 	 	 	 
	 

	 	 

C. Daniel Myers
	 	 
	 
	 	 	 	 
	 

	 	 

David Holland
	 	 
	 
	 	 	 	 
	 

	 	 

Alisa Hudzina
	 	 
	 
	 	 	 	 
	 

	 	 

Susan Caballa
	 	 
	 
	 	 	 	 
	 

	 	 

David Eitel
	 	 

Signature Page to

Alimera Sciences, Inc.

Omnibus Amendment

 

 

Attachment 1

Series C-1 Investors

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Series C-1 Shares
	 	 	Series C-1 Closing 	 	 Issuable upon 
	Name of Investor	 	Shares 	 	Warrant Exercise
	Venrock Associates IV, L.P.
	 	 	429,125	 	 	 	858,250	 
	 
	 	 	 	 	 	 	 	 
	Venrock Entrepreneurs’ Fund IV, L.P.
	 	 	10,544	 	 	 	21,088	 
	 
	 	 	 	 	 	 	 	 
	Venrock Partners, L.P.
	 	 	87,512	 	 	 	175,024	 
	 
	 	 	 	 	 	 	 	 
	Intersouth Partners VII, L.P.
	 	 	421,257	 	 	 	842,514	 
	 
	 	 	 	 	 	 	 	 
	Intersouth Partners V, L.P.
	 	 	219,787	 	 	 	439,574	 
	 
	 	 	 	 	 	 	 	 
	Intersouth Affiliates V, L.P.
	 	 	10,074	 	 	 	20,148	 
	 
	 	 	 	 	 	 	 	 
	BAVP, L.P.
	 	 	651,118	 	 	 	1,302,236	 
	 
	 	 	 	 	 	 	 	 
	Domain Partners VI, L.P.
	 	 	644,214	 	 	 	1,288,428	 
	 
	 	 	 	 	 	 	 	 
	DP VI Associates, L.P.
	 	 	6,904	 	 	 	13,808	 
	 
	 	 	 	 	 	 	 	 
	Polaris Venture Partners IV, L.P.
	 	 	639,425	 	 	 	1,278,850	 
	 
	 	 	 	 	 	 	 	 
	Polaris Venture Partners
Entrepreneurs’ Fund IV, L.P.
	 	 	11,693	 	 	 	23,386	 
	 
	 	 	 	 	 	 	 	 
	The Calvin W. Roberts MD PC Pension
Plan
	 	 	46,000	 	 	 	92,000	 
	 
	 	 	 	 	 	 	 	 
	Janice Dee Weber
	 	 	543	 	 	 	1,086	 
	 
	 	 	 	 	 	 	 	 
	REDLOH Capital, LLC
	 	 	4,857	 	 	 	9,714	 
	 
	 	 	 	 	 	 	 	 
	BFG Investments LLC
	 	 	12,960	 	 	 	25,920	 
	 
	 	 	 	 	 	 	 	 
	Thomas L. Shields, Jr.
	 	 	4,828	 	 	 	9,656	 
	 
	 	 	 	 	 	 	 	 
	C&B Capital II, L.P.
	 	 	35,355	 	 	 	70,710	 
	 
	 	 	 	 	 	 	 	 
	C&B Capital II (PF), L.P.
	 	 	29,020	 	 	 	58,040	 

 

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Series C-1 Shares
	 	 	Series C-1 Closing 	 	 Issuable upon 
	Name of Investor	 	Shares 	 	Warrant Exercise
	James Loftin
	 	 	1,107	 	 	 	2,214	 
	 
	 	 	 	 	 	 	 	 
	Michel Benton
	 	 	543	 	 	 	1,086	 
	 
	 	 	 	 	 	 	 	 
	Linda T. and Jimmy D. Veal
	 	 	7,818	 	 	 	15,636	 
	 
	 	 	 	 	 	 	 	 
	Daniel D. Veal
	 	 	1,201	 	 	 	2,402	 
	 
	 	 	 	 	 	 	 	 
	Zachary T. Veal
	 	 	1,201	 	 	 	2,402	 
	 
	 	 	 	 	 	 	 	 
	Plunkett Family LP
	 	 	3,622	 	 	 	7,244	 
	 
	 	 	 	 	 	 	 	 
	G&H Partners
	 	 	10,000	 	 	 	20,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]